However, the first-in-human trials using systemic rhIL15 and IL15 super agonist complexes in patients treated with haploidentical NK cell therapy for advanced AML, showed expansion of host CD8+ T cells which resulted in CRS and rejection of allogeneic donor NK cells [10, 37]. The gene discussed is CD8A; the disease is congenital rubella syndrome.